Related Experiment Video
Updated: Feb 20, 2026
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
MtHsp70-CLIC1-pulsed dendritic cells enhance the immune response against ovarian cancer
Wentao Yu1, Hong Qu1, Guangming Cao1
1Department of Obstetrics & Gynecology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Abstract:
Approximately 80% of ovarian cancer (OC) is diagnosed at late stages, and most patients die within 5 years of diagnosis due to recurrence or drug resistance. Novel treatments are required to improve patient survival. Immune therapy against cancer is promising; however, therapeutic vaccination has been limited by the inability of tumor antigens to induce effective immune responses. Chloride intracellular channel 1 (CLIC1) was previously identified as a possible tumor marker for OC. In this study, we constructed a recombinant protein by conjugating the extracellular domain of CLIC1 to the carboxyl terminus of Mycobacterium tuberculosis heat shock protein 70 (MtHsp70). Human dendritic cells (DCs) derived from cortical blood were pulsed with the fusion protein, and the antitumor effect of human cytotoxic T lymphocytes (CTLs) stimulated by autologous DCs was assessed in NOG mice. MtHsp70-CLIC1 promoted the phenotypic maturation of human DCs and the secretion of Th1-associated cytokines in vitro. MtHsp70-CLIC1-stimulated CTLs generated a CLIC1-specific immune response both in vitro and in vivo. These results indicate that DCs pulsed with MtHsp70-CLIC1 can enhance antitumor immunity against OC, providing a novel immune therapeutic strategy.
Insights
A novel immunotherapy using a fusion protein (MtHsp70-CLIC1) shows promise for ovarian cancer (OC). This approach enhances dendritic cell maturation and stimulates cytotoxic T lymphocytes (CTLs) to target CLIC1, improving antitumor immunity.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Ovarian cancer (OC) is often diagnosed late, with high recurrence and drug resistance rates, necessitating novel treatments.
- Current cancer immunotherapies, like therapeutic vaccination, face limitations due to tumor antigens failing to elicit effective immune responses.
- Chloride intracellular channel 1 (CLIC1) has been identified as a potential tumor marker for OC.
Purpose of the Study:
- To develop and evaluate a novel immunotherapy strategy for ovarian cancer using a fusion protein approach.
- To assess the efficacy of dendritic cells (DCs) pulsed with a fusion protein in stimulating an antitumor immune response.
Main Methods:
- A recombinant fusion protein, MtHsp70-CLIC1, was constructed by linking the extracellular domain of CLIC1 to Mycobacterium tuberculosis heat shock protein 70 (MtHsp70).
- Human dendritic cells (DCs) were pulsed with the MtHsp70-CLIC1 fusion protein.
- The immune response of cytotoxic T lymphocytes (CTLs) stimulated by these DCs was evaluated in vitro and in NOG mice models.
Main Results:
- The MtHsp70-CLIC1 fusion protein promoted the phenotypic maturation of human DCs and increased the secretion of Th1-associated cytokines.
- DCs pulsed with MtHsp70-CLIC1 successfully stimulated CTLs to generate a CLIC1-specific immune response.
- This immune response was observed both in vitro and in vivo, demonstrating an enhancement of antitumor immunity.
Conclusions:
- Dendritic cells pulsed with the MtHsp70-CLIC1 fusion protein represent a viable strategy for enhancing antitumor immunity against ovarian cancer.
- This novel approach offers a potential new avenue for immune therapeutic intervention in OC treatment.
Related Concept Videos
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:27Tumor Immunotherapy